Clinical trial

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in…

NCT01320202 · Rockwell Medical Technologies, Inc., Industry · Completed

Key facts

NCT number NCT01320202
Title Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
Official title A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1) Study
Acronym CRUISE 1
Lead sponsor Rockwell Medical Technologies, Inc., Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Renal Failure Chronic Requiring Hemodialysis
Intervention type Device, Drug
Interventions Soluble Ferric Pyrophosphate (SFP), Standard dialysate
Enrollment 305
Start date Mar 1, 2011
Primary completion May 1, 2013
Completion Nov 1, 2013
First posted Mar 22, 2011
Last update posted Apr 26, 2017
Countries Puerto Rico, United States

At a glance

  • 1–9 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies